Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens by Sugarman, Elaine A et al.
ARTICLE
Pan-ethnic carrier screening and prenatal diagnosis
for spinal muscular atrophy: clinical laboratory analysis
of 472400 specimens
Elaine A Sugarman1, Narasimhan Nagan*,1, Hui Zhu1, Viatcheslav R Akmaev1, Zhaoqing Zhou1,
Elizabeth M Rohlfs1, Kerry Flynn1, Brant C Hendrickson1, Thomas Scholl1, Deborah Alexa Sirko-Osadsa1
and Bernice A Allitto1
Spinal muscular atrophy (SMA) is a leading inherited cause of infant death with a reported incidence of B1 in 10000 live
births and is second to cystic ﬁbrosis as a common, life-shortening autosomal recessive disorder. The American College of
Medical Genetics has recommended population carrier screening for SMA, regardless of race or ethnicity, to facilitate informed
reproductive options, although other organizations have cited the need for additional large-scale studies before widespread
implementation. We report our data from carrier testing (n¼72453) and prenatal diagnosis (n¼121) for this condition.
Our analysis of large-scale population carrier screening data (n¼68471) demonstrates the technical feasibility of high
throughput testing and provides mutation carrier and allele frequencies at a level of accuracy afforded by large data sets.
In our United States pan-ethnic population, the calculated a priori carrier frequency of SMA is 1/54 with a detection rate of
91.2%, and the pan-ethnic disease incidence is calculated to be 1/11000. Carrier frequency and detection rates provided for
six major ethnic groups in the United States range from 1/47 and 94.8% in the Caucasian population to 1/72 and 70.5% in the
African American population, respectively. This collective experience can be utilized to facilitate accurate pre- and post-test
counseling in the settings of carrier screening and prenatal diagnosis for SMA.
European Journal of Human Genetics (2012) 20, 27–32; doi:10.1038/ejhg.2011.134; published online 3 August 2011
Keywords: spinal muscular atrophy (SMA); pan-ethnic; carrier screening; SMN1
INTRODUCTION
Spinal muscular atrophy (SMA) is a severe neuromuscular disease
characterized by degeneration of the anterior motor neurons, leading
to progressive muscle weakness and paralysis. SMA is the leading
inherited cause of infant death1 with an incidence of B1/10000.2
Childhood SMA is subdivided based on age of onset and clinical
severity into three types.3 Approximately 60% of SMA patients have
type I (Werdnig–Hoffman) disease,4 with severe generalized muscle
weakness and hypotonia presenting at birth or within the ﬁrst few
months of life and respiratory failure leading to death or permanent
ventilator support by 2 years of age. Type II accounts for B27% of
SMA,4 and is variable, with some children having severe respiratory
insufﬁciency and transient ability to sit, whereas others have milder
respiratory involvement and are mobile with mechanical support.
Individuals with type III SMA (Kugelberg–Welander) experience
delayed motor milestones, mild muscle weakness and fatigue.
SMA is caused by mutations in the survival motor neuron 1
(SMN1)g e n e . 4 The SMN1 gene is located in a complex region of
5q13 containing SMN2, a homologous pseudogene of SMN1. SMN1
and SMN2 differ by ﬁve nucleotides, one of which is in the coding
region, in exon 7. This sequence change affects splicing resulting in
reduced expression of full-length functional protein from the SMN2
gene.5 The homozygous absence of SMN1, due to deletion or gene
conversion (of SMN1 to SMN2) is responsible for B95% of SMA.
Most of the remaining patients are compound heterozygotes with a
deletion/gene conversion of the SMN1 gene paired with an intragenic
mutation. Affected individuals lacking functional SMN1 retain at least
1 copy of SMN2. An inverse relationship between disease severity and
SMN2 copy number in affected individuals has been observed.6 Other
modifying factors, including SMN2 sequence variants, may also
inﬂuence phenotypic variability.7
Among normal alleles, 1-copy and 2-copy chromosomes are desi-
gnated as ‘1’ (b)a n d‘ 2 ’( c), respectively.4,8 Chromosomes resulting
from a deletion or gene conversion are referred to as a ‘0’ (a), whereas
those with subtle SMN1 intragenic mutations are referred to as ‘1d’( d).4
Determination of SMN1 copy number in a general carrier screening
population permits identiﬁcation of the majority of SMA carriers
before the birth of an affected child. Initial reports of SMN1 copy
number quantiﬁcation focused on diagnostic testing for affected
individuals without a homozygous deletion and carrier testing for
individuals with a family history of SMA.9 In 2002, Ogino et al2
reported testing 663 asymptomatic individuals by SMN1 copy number
analysis, the majority (71%) of whom had a family history of
conﬁrmed or suspected SMA. Subsequently,10–12 studies from around
the world including Australia,13 Korea,14 Taiwan,11 Israel,15,16 China17
and the United States18 have called for screening individuals without a
family history of SMA for carrier status, citing disease severity and a
high pan-ethnic carrier frequency. In 2008, the American College of
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www.nature.com/ejhgMedical Genetics (ACMG) issued practice guidelines recommending
all couples be offered SMA carrier screening, regardless of race or
ethnicity, with the goal of allowing identiﬁed carriers to make
informed reproductive choices.19 The guidelines identiﬁed SMA as
meeting generally accepted criteria for a successful screening program
including clinical severity, a high frequency of carriers in the screened
population, reliable testing with high sensitivity and speciﬁcity, avail-
able prenatal diagnosis and access to genetic counseling. In 2009, a
conference at the US National Institutes of Health reviewed the
scientiﬁc basis of SMA carrier screening and concluded that pan-
ethnic carrier screening for SMA is technically feasible.20 Recently, the
Association for Molecular Pathology (AMP) issued a statement
recognizing the utility and feasibility of population-based SMA carrier
screening.21 Among the speciﬁc recommendations identiﬁed were the
needs to offer pilot screening programs and determine SMA carrier
frequency among different ethnic groups so as to improve risk
assessment and post-test counseling. In 2009, the American College
of Obstetricians and Gynecologists (ACOG) recommended restricting
carrier screening to individuals with a family history of SMA. ACOG
asserted that assessment of pilot programs, educational materials, cost
effectiveness of screening and absence of laboratory standards and
guidelines should be considered before widespread implementation of
ac a r r i e rs c r e e n i n gp r o g r a mf o rS M A . 22 Several recent reports address
these issues.18,20
We report our SMA carrier screening data for 468400 individuals
without a family history of SMA. Our ﬁndings indicate a rapid test
uptake beginning before the ACMG guidelines, and further support
patient interest in the availability of SMA carrier screening. Further-
more, our data permit reﬁnement of carrier frequency and detec-
tion rate information for six major ethnic groups and the general,
pan-ethnic population and address the call for a large-scale population
screening study.
MATERIALS AND METHODS
Patient’s samples
Clinical laboratory data were reviewed for 72453 individuals and 121 fetal
samples referred for SMN1 copy number analysis over a 12-month time
period beginning in May 2008. Relevant information including the clinical
indication for testing, family history and ethnicity was obtained by review of
the test requisition forms. All individuals referred for testing were reportedly
asymptomatic. For clinical testing, it is standard for the referring physician
to obtain informed consent, therefore an ethics approval was not required.
Individuals referred for testing spanned 44 US states, the District of Columbia
and Puerto Rico.
Quantitative real time PCR analysis and sequencing
DNA was isolated from blood specimens, using a modiﬁcation of the Qiagen
QIAmp 96 DNA Blood Kit (Qiagen GmbH, Hilden, Germany, http://www.
qiagen. com). DNA from prenatal cultured AF or CVS specimens was isolated
using a modiﬁed salting-out method. Multiplex ampliﬁcations and qPCR
measurements were performed on the ABI Prism 7900HT Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA). Each reaction utilized
standard Taqman PCR reagents in total volume of 20ml containing 180ng of
DNA, 0.9mM of SMN1 primers (SMN1FP-5¢-ATAGCTATTTTTTTTAACTT
CCTTTATTTTCC-3¢ and SMN1RP-5¢-CTTACTCCTTAATTTAAGGAATGTG
AGCA-3¢) and each of two internal standard reference gene primers (SMA
RCC1FP-5¢-AGGTACCACTGGAATTGGTTGAA-3¢,S M A R C C 1 R P - 5 ¢-CATATA
TTAACCCTGTCCCTTAAAAGCA-3¢, SUPT5HFP-5¢-CACGTGAAGGTGATT
GCTGG-3¢, SUPT5HRP-5¢-CGACCCTTCTATCCACCTACCTC-3¢), 0.2mM
each of the SMN1-speciﬁc FAM-TAMRA hydrolysis probe (5¢-AGGGTTTCAG
ACAAAATCAAAAAGAAGGAAG-3¢), reference gene-speciﬁc VIC-TAMRA
hydrolysis probes (SMARCC1-5¢-AGTACAAGAAGCAGCACGAGCCTCTG-3¢
and SUPT5-5¢-CGTTATCCTGTTCTCTGACCTCACCATG-3¢) and a competitive,
non-ﬂuorescent, non-hydrolysable probe speciﬁc for SMN2 (5¢-AGGGTTTTA
GACAAAATCAAAAAGAAGGAAGG-3¢). Thermal cycling conditions included
an initial denaturation of 10min at 951C followed by 40 cycles of 15s at 951C
and 1min at 601C. Sequencing of primer and probe binding sites was
performed on all prenatal specimens, and blood specimens with an
SMN1 copy number of o2, by bidirectional sequence analysis using BigDye
Terminator Cycle Sequencing Kit (version 3.1) followed by capillary electro-
phoresis (Applied Biosystems, Carlsbad, CA, USA).
Data evaluation was performed using the Cq (quantiﬁcation cycle)
data exported from SDS 2.2 software (Applied Biosystems, Foster City, CA,
USA). The formula (2).(2)DDCq,w h e r eDDCq¼(SMN1 Cq–reference gene
Cq)–average DCq of 2-copy calibrators, was utilized to estimate the SMN1
copy number. Each control and test sample included a copy number CV
(coefﬁcient of variation) cutoff of 0.15 between replicate measurements. All
results could be assigned to validated, non-overlapping genotype groups of 0, 1,
2o rZ3 copies of SMN1.
Statistical analysis
The 95% conﬁdence intervals around genotype frequency estimates (Table 1)
were calculated based on the exact beta distribution model. The derived allele
frequencies (Table 2) are maximum likelihood estimates calculated from
observed genotype data under assumption of Hardy–Weinberg equilibrium.
An EM algorithm was employed to account for missing observations of 0-copy
SMN1 genotype in the screening population. The algorithm converged to six
signiﬁcant digits in estimating allele frequencies after two iterations. The 95%
conﬁdence interval around allele frequency estimates and the previous risk
estimates (Tables 2 and 3) were calculated as the corresponding percentiles of
simulated populations of allele frequencies and risk estimates. These Monte
Carlo simulations were based on 10000 random genotype observations
generated from the posterior beta distribution followed by maximum
Table 1 Observed SMN1 genotype frequencies among carrier screening referrals (n¼68471)
1-copy 2-copy Z3-copy
Ethnicity n %9 5 % C I n %9 5 % C In %9 5 % C I T o t a l
Pan-ethnica 1162 1.7 (1.6–1.8) 58094 84.84 (84.6–85.1) 9215 13.46 (13.2–13.7) 68471
Caucasian 494 2.02 (1.9–2.2) 22252 90.93 (90.6–91.3) 1725 7.05 (6.7–7.4) 24471
Ashkenazi Jewish 78 1.34 (1.1–1.7) 4913 84.62 (83.7–85.5) 815 14.04 (13.2–15.0) 5806
Asian 73 1.57 (1.3–2.0) 4148 89.26 (88.4–90.1) 426 9.17 (8.4–10.0) 4647
Hispanic 101 1.32 (1.1–1.6) 6406 83.68 (82.9–84.5) 1148 15.0 (14.2–15.8) 7655
Asian Indian 17 1.74 (1.1–2.8) 808 82.79 (80.4–85.1) 151 15.47 (13.4–17.9) 976
African American 48 0.98 (0.7–1.3) 2536 51.94 (50.5–53.3) 2299 47.08 (45.7–48.5) 4883
Not provided 290 1.68 (1.5–1.9) 14645 84.97 (84.4–85.5) 2300 13.35 (12.8–13.9) 17235
Abbreviation: CI, conﬁdence interval.
a2798 individuals of mixed or other ethnicity are included in the pan-ethnic total of 68471.
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tion. The w2-test with Yates correction was used for comparison of 1-copy
genotype frequencies between populations.
RESULTS
Population-based carrier screening
Approximately 95% of the 72453 individuals referred for carrier
testing had no family history of SMA. This ethnically diverse carrier
screening population was comprised of 68471 individuals, 94% of
whom were female. For analysis purposes, our study population was
categorized by ethnicity according to information provided on the
test requisition. Ethnicity-speciﬁc risk calculations were generated for
six ethnic groups (Caucasian, Ashkenazi Jewish, Hispanic, African
American, Asian, Asian Indian) and for individuals for whom
ethnicity was ‘Not Provided’ resulting in a total of seven categories.
Pan-ethnic calculations included individuals from these categories as
well as those reporting multiple or other ethnicities (n¼2798). The
SMN1 allele frequencies (a,b,c) derived from the observed genotype
frequencies (Table 1) are listed in Table 2. For the purpose of this
study, the allele frequency of intragenic SMN1 point mutations (d),
was presumed to be constant across ethnic groups based upon an
earlier report describing SMN1 deletion/gene conversion and point
mutation distribution among 501 affected patients.23 The calculated
SMA carrier frequency and SMN1 deletion detection rate for the
pan-ethnic population and each of seven categories are listed in
Table 3. The calculated carrier frequency is the a priori risk for an
individual to be a carrier and includes the probability of the most
likely allele pairings expected to occur among carriers in the general
population, namely [1+0], [1+1d], [2+0] and [2+1d]. The SMN1
deletion detection rate (or sensitivity of the carrier test result) is
the percentage of carriers with the [1+0] genotype (who will be
identiﬁed by a 1-copy result), among all carriers of SMA (as deter-
mined by the carrier frequency). The reduced carrier risk following
a 2- or 3-copy result in an individual with no family history of SMA
is listed in Table 3.
The calculated pan-ethnic carrier frequency of 1/54 (Table 3) is
consistent with the frequency of 1/40–1/60 frequently cited in the
literature.13 The carrier frequencies among each of the ethnic groups
ranged from 1/47 in the Caucasian population to 1/72 in the African-
American population. The carrier detection rate in the pan-ethnic
screening population is 91.2%. Among the seven categories for whom
prior carrier risk and carrier detection rate is calculated (Table 2), all
but African Americans have a detection rate exceeding 90% and an a
priori risk in the range of 1/47–1/68.
The carrier detection rate in the African American population is
70.5%. This ﬁnding from our large scale clinical experience conﬁrms
our earlier observation24 of a decreased carrier detection rate (Table 3)
due to an associated increased 2-copy (c) allele frequency (Table 1) in
the African American population. Furthermore, the estimated nega-
tive predictive value of the carrier test as calculated by the derived
allele pairings, was 499% for both the pan-ethnic group as well as
each of the six major ethnic subgroups.
Other carrier test indications
Among 72453 individuals referred for carrier testing, greater than
95% (n¼68945), had an indication for testing provided by the
referring physician. The 4.8% (n¼3508) of referrals for whom no
indication was provided, were excluded from further analysis,
although they were most likely referred for carrier screening, as 95%
of these samples were from women of reproductive age. Fewer
than 1% (n¼329) of individuals referred for carrier testing had
indications of a family history of SMA (including obligate carriers)
or abnormal fetal ultrasound ﬁndings. Of the 71 individuals referred
for an indication of abnormal fetal ultrasound ﬁndings, the most
frequent ﬁndings were increased nuchal translucency (n¼17) and
cystic hygroma (n¼4) in the ﬁrst trimester and joint contractures
(n¼18) and increased nuchal fold (n¼10) in the second trimester.
Three individuals were identiﬁed as carriers; all others, including
the partners of these carriers, had a 2- or 3-copy result. Among the
three carriers, only one had fetal SMA testing in our laboratory and
the fetus had 2 SMN1 copies. These results indicate that SMA may
be included as a differential diagnosis following identiﬁcation of
suggestive abnormal fetal ultrasound ﬁndings.
Table 2 Derived SMN1 allele frequencies
Ethnicity (number of individuals)a 0-copy (%) (a) 95% CI (%) 1-copy (%) (b) 95% CI (%) 2-copy (%) (c) 95% CI (%) 1d (%) (d)
Pan-ethnic (N¼68471) 0.92 (0.87–0.98) 92.02 (91.86–92.17) 7.04 (6.90–7.18) 0.02
Caucasian (N¼24471) 1.06 (0.97–1.16) 95.3 (95.09–95.48) 3.63 (3.47–3.80) 0.02
Ashkenazi Jewish (N¼5806) 0.73 (0.59–0.91) 91.91 (91.36–92.39) 7.34 (6.88–7.84) 0.02
Asian (N¼4647) 0.83 (0.66–1.05) 94.42 (93.90–94.87) 4.74 (4.31–5.19) 0.02
Hispanic (N¼7655) 0.72 (0.59–0.88) 91.4 (90.92–91.86) 7.86 (7.43–8.31) 0.02
Asian Indian (N¼976) 0.96 (0.60–1.54) 90.88 (89.36–92.09) 8.15 (6.98–9.48) 0.02
African American (N¼4883) 0.68 (0.52–0.91) 71.79 (70.73–72.76) 27.51 (26.57–28.51) 0.02
Not provided (N¼17235) 0.91 (0.81–1.03) 92.09 (91.78–92.38) 6.98 (6.71–7.26) 0.02
Abbreviation: CI, conﬁdence interval.
aNumber of individuals with no family history of SMA referred for SMN1 copy number analysis by ethnic background.
Table 3 Carrier frequency and risk reduction by ethnicity
Ethnicity
Detection
rate (%)
a priori riska
(95% CI)
Reduced
risk for
2-copy result
Reduced
risk for
Z3-copy result
Pan-ethnic 91.2 1:54 (1:51–1:57) 1:527 1:5400
Caucasian 94.8 1:47 (1:43–1:51) 1:834 1:5600
Ashkenazi Jewish 90.5 1:67 (1:54–1:83) 1:611 1:5400
Asian 93.3 1:59 (1:47–1:74) 1:806 1:5600
Hispanic 90.0 1:68 (1:57–1:83) 1:579 1:5400
Asian Indian 90.2 1:52 (1:33–1:82) 1:443 1:5400
African American 70.5 1:72 (1:54–1:94) 1:130 1:4200
Not provided 91.3 1:54 (1:48–1:161) 1:536 1:5450
aap r i o r irisk includes the [1+0], [1+1d], [2+0] and [2+1d] allele pairings for individuals with no
family history of spinal muscular atrophy.
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A total of 121 fetal samples (51 cultured chorionic villi and 70
amniocyte) were received for SMN1 copy number analysis. Of the
54 fetuses at a 25% risk to be affected with SMA, 47 were based on a
previous affected child, four on identiﬁcation of parental carrier status
following carrier screening and three had both parents identiﬁed as
carriers at other laboratories. Fifteen of the 54 (27.8%) were predicted
to be affected with SMA, based on a 0-copy result from testing. This
result is consistent with the expected 25% frequency given autosomal
recessive inheritance (P¼0.26).
In all, 59 fetuses were tested after identiﬁcation of carrier status in one
parent, with the other parent having a 2- or 3-copy result determined
concurrently or before fetal testing. Of these, 27 fetuses had 1 copy and 32
had 2 copies of SMN1. At least 53 of the 59 had an indication for CVS or
amniocentesis that was unrelated to the parental SMA carrier testing (eg,
advanced maternal age, abnormal maternal serum screen). The remaining
six samples were received as cultured cells from outside laboratories. The
indication for the prenatal diagnostic procedure in these cases was not
readily available, although the average age of these mothers was 37 years.
Seven of the 121 fetal samples were referred based on abnormal
ultrasound ﬁndings such as joint contractures suggestive of SMA, and
all had 2-copy fetal results. Lastly, one sample was tested due to a
reported family history of SMA, although neither parent was identiﬁed as
a 1-copy carrier and the fetus had 2 copies of SMN1.
Sequence variants that interfere with SMN1 copy number
determination
To rule out false positive results due to the presence of sequence
variants under the primer and probe-binding sites used in our
analysis, follow-up sequencing restricted to these sites was performed
on all samples with 1 copy of SMN1 and all prenatal specimens
regardless of SMN1 copy number. This led to the identiﬁcation of a
recurrent variant, NT_006713.14:c.865T4A (g.29631T4A; p. C289S),
in a heterozygous state among 35 individuals. This variant was
most frequent among Hispanic individuals (n¼19) but was
also identiﬁed in Ashkenazi Jewish and Caucasian (n¼9 combined)
individuals and in individuals for whom ethnicity information
was not provided to the laboratory (n¼7). Another variant,
NT_006713.14:c.867C4T (g.29633C4T; p.C289C) was identiﬁed in
a heterozygous state in one Hispanic individual. Both these variants
resulted in a 1-copy result by our real time PCR methodology and
were subsequently identiﬁed by sequence analysis to be present in a
heterozygous state within the SMN1 gene as evidenced by presence
of the nucleotide ‘C’ at the critical position, c.840 that distinguishes
SMN1 from SMN2. Neither of these variants was observed in a homo-
zygous state among individuals analyzed. Our practice of restricting
follow-up sequence analysis to individuals identiﬁed to have 1 copy of
SMN1 precludes an accurate estimation of the general population
allele frequency of these variants.
DISCUSSION
SMA affects individuals of all ethnicities. The estimated pan-ethnic
disease frequency, (a+d),2 derived from our carrier frequency data
(1/11000, Table 2) is consistent with the reported prevalence estimate
of 1/10000 reported for clinically typical SMA derived from larger
population studies.4 Previous reports on SMA carrier frequen-
cies in limited populations have identiﬁed a discrepancy between
the estimated disease prevalence (1/10000) and that extrapolated
from observed carrier frequency estimates (1/6000) under Hardy–
Weinberg equilibrium. Although possible explanations for the earlier
discrepancies have been proposed,4 our present study is the ﬁrst to
report a pan-ethnic carrier frequency that is most consistent with the
reported incidence of SMA.
For purposes of genetic counseling within the setting of population-
based carrier screening, pan-ethnic carrier frequency (1/54) and
carrier detection rate (91%) data are particularly useful when ethnicity
is unknown or reﬂects admixture. When ethnicity is known, however,
it may be possible to further reﬁne the carrier frequency or detection
rate provided in pre-test education and counseling, as well as provide
more accurate estimates of residual risk following identiﬁcation of a
2- or 3-copy SMN1 result. For instance, a Caucasian individual with a
2-copy result following carrier screening would have an B1/800
residual risk to be a carrier, whereas an African American individual
with the same result would have a 1/130 risk to be a carrier.
Testing 4883 African American individuals with no family history of
SMA conﬁrmed earlier observations24 of a higher frequency of the 2-copy
allele (c) in this population as compared with other populations. This
suggests a higher frequency of [2+0] carriers who would not be identiﬁed
by an assay designed to detect deletion carriers who have 1 copy of
SMN1. This is accurately reﬂected by the lower detection rate of 71% in
this population. The a priori risk for an African American individual to
be a carrier (1/72) is, however, comparable to other populations and
supports the inclusion of African Americans among those being offered
carrier screening for SMA, with appropriate counseling regarding the
limitations of testing and associated residual risks.
In this study of 7655 Hispanic individuals, the observed SMN1
1-copy frequency did not differ signiﬁcantly from that observed in our
earlier study24 of 1030 individuals (P¼0.1869). In the Asian carrier-
screening population, pair-wise comparison of observed SMN1 1-copy
frequency between our current data set (n¼4647) and those of our
earlier study24 (n¼1027), as well as studies in native Chinese17
(n¼1712) and Korean14 (n¼326) populations, also did not yield
signiﬁcant differences at 1% (P-values¼0.7776, 0.0366, 0.5674, respec-
tively). Among individuals identiﬁed as Asian Indian (n¼976), the
1-copy genotype frequency was 1.74% with a calculated a priori carrier
frequency of 1/52. We are not aware of previous studies of SMA carrier
frequency in the general Asian Indian population. Similarly, the SMN1
1-copy genotype frequency distribution in our Ashkenazi Jewish
population was not signiﬁcantly different from that reported in the
Israeli population16 (P¼0.6575). Finally, an evaluation of genotype
frequencies for individuals whose ethnic background was ‘Not Pro-
vided’ on the ordering test requisition supports the conclusion that
the ethnicity distribution of this group does not differ from that of the
pan-ethnic population as a whole as the 1-copy genotype frequencies
are similar (P¼0.9217).
At least seven couples with no family history of SMA in our carrier-
screening population were identiﬁed as carriers with a 25% risk to
have an affected child. As a reference laboratory we do not have
complete ascertainment of family samples, and it is possible that some
partners of individuals identiﬁed as carriers via screening were tested
at other laboratories. Additionally, we could have incomplete ascer-
tainment if partners were not identiﬁed as such on ordering paper-
work or if a fetal sample from carrier parents was tested at another
laboratory. Of the seven couples, four had fetal testing in our
laboratory and no affected fetuses were identiﬁed in this small group.
Among individuals with a family history of SMA, there have
been case reports of ﬁrst-degree relatives with an SMN1 copy number
of 0 who are asymptomatic or mildly affected.25 This raises the
question of the frequency of individuals with 0 copies of SMN1 in
the general population. Among the 72453 samples tested, we did
not identify any individuals referred for carrier testing with an
apparent 0-copy SMN1 result.
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primer/probe region underscores the importance of this additional
quality assurance measure to identify potential false positive results.
These individuals could be misclassiﬁed as being carriers of a deletion/
gene conversionwithin the SMN1 gene. At present, there is insufﬁcient
evidence to classify these variants as either disease causing or benign.
Therefore, although the SMN1 copy number of individuals identiﬁed
with these variants can be reclassiﬁed, their SMA carrier status
and associated residual risk cannot be accurately determined at
present. Follow-up options, such as carrier testing of the partner
can be explored. In the absence of follow-up sequencing, the estimated
pan-ethnic-positive predictive value of our carrier analysis (TP (1162)/
TP (1162)+FP (36)) would have been 97%.
In our prenatal testing cohort, as expected, B25% of the at-risk
fetuses were found to have 0 copies of SMN1 and were predicted to be
affected with SMA. Among 54 fetal samples referred for testing due to
a 25% risk to be affected, 47 were from obligate carrier parents with
a previous affected child. Of these, eight obligate carriers (8.5%) had
2 copies of SMN1 and a partner with 1 copy of SMN1.T h i sf r e q u e n c y
is consistent with the frequency of 7/117 (6.0%) obligate carrier
parents identiﬁed to have 2 copies of SMN1 as reported by Smith
et al18 (P¼0.79). In our study, additional studies to distinguish the
[2+0] versus [1+1] status of these 2-copy obligate carrier parents were
not performed. Therefore, the exact frequency of 2-copy chromo-
somes in our obligate carrier parent cohort cannot be determined.
A lack of agreement exists among the limited number of
studies investigating a relationship between abnormal ultrasound
ﬁndings and SMA. Some reports suggest an association between
increased nuchal translucency and SMA,26 although this associa-
tion has not been supported by all studies.27 The inclusion of
abnormal ultrasound ﬁndings among indications for carrier testing
and prenatal diagnosis within our study suggests possible physician
interest in including SMA among the differential diagnoses for
select ultrasound abnormalities, although we are unable to determine
the frequency with which parents or fetuses with these ﬁndings are
referred for SMA testing.
The most frequent indication for fetal testing (49%) was having
one carrier parent identiﬁed during screening. In these circumstances,
the other parent was identiﬁed as having 2 or 3 copies of SMN1 or was
tested for carrier status concurrently with the fetal SMN1 copy
number analysis. In all but six samples for which clinical indication
could not be conﬁrmed, invasive prenatal diagnosis was performed for
a reason unrelated to the carrier parent’s SMN1 status. It is presumed
that fetal testing was pursued in the interest of time in these cases, as
was the case for individuals in whom the fetal sample and the untested
parent were analyzed at the same time, or for additional reassurance.
The a priori risk for a fetus to be affected with SMA, when
one parent is identiﬁed as a 1-copy carrier and the other parent has
an SMN1 copy number of 2, can vary by ethnic background. In
a Caucasian couple, the risk to have an affected fetus is 1/2528.
In contrast, the risk for an African American couple with the same
parental results is 1/264. SMN1 copy number analysis for a fetus in
this circumstance could reveal a 0-copy SMN1 result, consistent with
a prediction for the fetus to be affected. In addition, such a result
would set the parental phase for the 2-copy parent as a [2+0] carrier.
Alternatively, a 1-copy fetal result in this situation would be associated
with an B1/4000 risk for the fetus to be affected with SMA, due to
compound heterozygosity for a 1d (d) allele.
In a pilot study of general population carrier screening in the
United States, Prior et al18 reported B60% of individuals seeking
prenatal genetic counseling accepted carrier testing for SMA. After
result disclosure, 98.7% of patients were glad they pursued testing.
In Israel, among women electing carrier screening for cystic ﬁbrosis
and fragile X syndrome, a large-scale population screening study
found 93% requested SMA testing as well.15 Our clinical laboratory
analysis of 468000 individuals without a family history of SMA,
starting before the 2008 ACMG guideline, demonstrates (1) rapid test
uptake by physicians and further supports patient interest in the
availability of carrier screening for this disorder; (2) the feasibility of
high throughput carrier testing for SMA; and (3) new
and valuable information regarding SMN1 copy number in the
general United States population to permit more accurate residual
carrier risk calculations based on ethnicity-speciﬁc carrier frequencies
and detection rates.
Furthermore, these data address speciﬁc recommendations set forth
by professional organizations such as the AMP and ACOG and fully
support the ACMG recommendations to offer SMA carrier screening
to all, regardless of race or ethnicity.
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